ABSTRACT
Primitive lymphomas of the bone are exceptional tumors, representing 4% of all non-Hodgkin lymphomas. The location at the skull remains the rarest. We report the case of a 56 year old patient with lytic lesions in the skull of a small cell lymphoma B, treated with primary chemotherapy and intensity-modulated radiotherapy in arctherapy with a dose of 30Gy in 15 fractions. With a follow-up time of 18 months after the end of treatment, the patient has no sign of disease evolution.
Subject(s)
Leukemia, Lymphocytic, Chronic, B-Cell/radiotherapy , Neoplasms, Second Primary/radiotherapy , Parietal Bone , Radiotherapy, Intensity-Modulated , Skull Neoplasms/radiotherapy , Adenine/analogs & derivatives , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Combined Modality Therapy , Craniotomy , Female , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/diagnostic imaging , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Magnetic Resonance Imaging , Meningeal Neoplasms , Meningioma , Middle Aged , Neoplasms, Second Primary/drug therapy , Osteolysis/etiology , Parietal Bone/diagnostic imaging , Parietal Bone/surgery , Piperidines , Protein Kinase Inhibitors/therapeutic use , Pyrazoles/therapeutic use , Pyrimidines/therapeutic use , Remission Induction , Skull Neoplasms/diagnostic imaging , Skull Neoplasms/drug therapyABSTRACT
Granulocytic sarcoma, or chloroma, is a rare clinical entity, usually associated with a blood disease, including acute myeloid leukemia. Management strategies are based on the combination of systemic therapy and local therapy (surgery or radiation). Data for radiotherapy dose are derived from retrospective studies and case reports. We conducted a literature review using the Pubmed search engine to clarify the terms and indications for radiotherapy of chloromas.
